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Abstract
Responses to hallucinogenic drugs, such as psilocybin, are believed to be critically dependent on the user’s personality,
current mood state, drug pre-experiences, expectancies, and social and environmental variables. However, little is known
about the order of importance of these variables and their effect sizes in comparison to drug dose. Hence, this study
investigated the effects of 24 predictor variables, including age, sex, education, personality traits, drug pre-experience,
mental state before drug intake, experimental setting, and drug dose on the acute response to psilocybin. The analysis was
based on the pooled data of 23 controlled experimental studies involving 409 psilocybin administrations to 261 healthy
volunteers. Multiple linear mixed effects models were fitted for each of 15 response variables. Although drug dose was
clearly the most important predictor for all measured response variables, several non-pharmacological variables significantly
contributed to the effects of psilocybin. Specifically, having a high score in the personality trait of Absorption, being in an
emotionally excitable and active state immediately before drug intake, and having experienced few psychological problems
in past weeks were most strongly associated with pleasant and mystical-type experiences, whereas high Emotional
Excitability, low age, and an experimental setting involving positron emission tomography most strongly predicted
unpleasant and/or anxious reactions to psilocybin. The results confirm that non-pharmacological variables play an
important role in the effects of psilocybin.
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Introduction
Responses to classical hallucinogens, such as psilocybin, strongly
vary between and within subjects, even when the drug dose is kept
constant [1,2]. It has therefore long been postulated that a large
proportion of inter- and intraindividual differences in reactions to
hallucinogens is determined by non-pharmacological variables –
also often referred to as set and setting. As originally defined by
Leary et al. [3], set refers to the preparation of the subject, his
personality structure, and current mood state, whereas setting
refers to the the physical, social, and cultural environment in
which the drug is taken. Although set and setting influence the
psychological effects of any psychotropic substance, including
alcohol and nicotine (e.g. see [4]), the effects of hallucinogens seem
to be particularly strongly determined by these conditions [1,5]. In
fact, they are not only said to be influenced by an individual
subject’s mental state and surroundings, but to pharmacologically
amplify the impact of these non-pharmacological factors on
human experience [6,7].
Since human hallucinogen research has been dormant for
almost three decades and has only come to a revival recently [8],
most of what we know today about non-pharmacological
predictors of hallucinogen response is based on a small number
of older studies, many of which do not conform to modern
methodological standards. Nevertheless, most of these studies
suggest that responses to classical hallucinogens are dependent at
least to some degree on the personality structure (e.g., [9–16]).
Further influencing factors include the mood state immediately
before drug intake (e.g., [14,17]), peer-support [18], estimated
emotional support [3], expectations of the subjects (e.g., [3,14,17]),
age [17,19], body morphology [17], size of the group in which the
drug is taken [3], and drug pre-experiences [3,17].
However, most of these studies have obtained only a limited
number of potential predictors at a time. Furthermore, almost all
of these studies have relied on simple correlations instead of
multiple regression to investigate associations between set and
setting variables and drug response. Thus, they did not adjust for
potentially confounding variables and also could not reveal the
order of importance of different variables. The only exception is a
study by Dittrich and his colleagues [14,20], which has used
multiple regression to predict responses to N,N-dimethyltrypta-
mine (DMT), nitrous oxide, and sensory deprivation from a large
number of different set and setting variables. Unfortunately, the
sample size of the DMT subgroup was relatively small (n= 45), and
the study so far has only been published in book chapters.
Given these methodological problems and given that a growing
number of investigators are using hallucinogens for experimental
and therapeutic purposes [8], new investigations on set and setting
are both timely and important. Beyond basic research, such
investigations could serve the following purposes. First, they can
help to improve the safety of controlled experiments using
hallucinogens by providing a basis for deciding which subjects to
exclude at screening and how to adjust the environment and
procedures for minimizing the risk of adverse reactions. Second,
they help to better standardize future experiments. For instance,
treatment allocation can be improved by stratifying experimental
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and control groups on the most important non-pharmacological
predictors and efforts in controlling confounding variables can be
better directed to those that really matter. Furthermore, the most
important predictors can be used for covariate adjustment in
randomized controlled trials, which improves precision and power
in the estimation of treatment effects [21]. Last but not least,
knowledge about non-pharmacological predictors can significantly
advance our understanding of the neurobiological systems
involved in the actions of hallucinogens. This is because individual
differences in personality, demographic characteristics, mood, etc.
on the one hand, and responsiveness to hallucinogens on the other
hand, could be both related to structural and functional differences
in specific neurotransmitter systems. In the case of psilocybin,
differences are most likely related to differential functioning and
density of cortical 5-HT2A receptors because this is the main site of
action of classical hallucinogens [22,23]. However, other receptors
(particularly the 5-HT1, 5-HT4, 5-HT5, 5-HT6, and 5-HT7
receptors) and neurotransmitter systems (particularly the gluta-
mate system), which are additionally involved in the actions of
classical hallucinogens [8,24], might also contribute to common
individual differences.
Thus, to further elucidate the dependency of psilocybin
response on set and setting, the present study investigates the
relative importance of 24 predictor variables, including age, sex,
years of education, body mass index, personality traits, drug pre-
experience, mental state before drug intake, psychological distress,
experimental setting, and drug dose. The analysis is based on the
pooled data of 23 controlled experimental studies. Most of these
have been published before as single studies. Additionally, data
from eight of the 23 pooled studies (i.e., those carried out between
2000 and 2008) were used in a recent pooled analysis on acute,
subacute, and long-term subjective effects of psilocybin [2] and
data from 20 studies (i.e., all but the three most recent studies)
were used in a recent psychometric investigation of the OAV
questionnaire [25]. However, none of these studies have yet
reported about the dependency of psilocybin effects on non-
pharmacological predictors.
This study improves on previous predictor studies in several
ways. First, the sample size (n = 409) is about four times as large as
in the largest previous study [3]. Second, the predictor variables
that we used covered a wide range of potentially important
domains, and the effects of these predictors were adjusted for the
most important confounders. Third, all outcome variables and
most of the predictor variables were measured by validated
instruments. Fourth, psilocybin was administered under highly
standardized research conditions. Finally, by using modern
statistical techniques, such as the bootstrap, more reliable estimates
of variable importance were obtained.
Methods
Ethics Statement
All studies were approved by the Ethics Committee of the
University Hospital of Psychiatry, Zurich, and the use of
psilocybin was authorized by the Swiss Federal Office of Public
Health, Department of Pharmacology and Narcotics, Berne. All
subjects gave their written consent after having received detailed
information about the aims of the studies, the experimental
procedures involved, and the effects and possible risks of
psilocybin administration. Subjects were reimbursed for their
time and free to withdraw from the study at any time. To
minimize potential risks of psilocybin administration, safety
guidelines similar to those recommended by Johnson et al. [26]
were followed in all studies.
Pooled Studies
The sample used in the present investigation was obtained by
pooling raw data from 23 experimental studies (including pilot
studies) involving psilocybin administration to healthy volunteers.
The studies were conducted at our research facility between 1992
and 2011 as part of a research program in which psilocybin was
used as a tool for pharmacological modeling of core symptoms of
schizophrenia and for studying cognitive, perceptual, and
emotional processes [23,27].
All pooled studies used placebo-controlled within-subject
designs. Depending on the study, subjects received placebo and
1–4 different doses of psilocybin in 2–5 experimental sessions, each
separated by at least two weeks to avoid carry-over effects. In six of
the pooled studies, subjects also received a receptor blocker (i.e.,
buspirone, ketanserin, haloperidol, lamotrigine, and risperidone)
alone and in combination with psilocybin. In the majority of the
studies (n = 16), the order of drug administration was randomized
and double-blind, but some of the earlier studies as well as most
pilot studies (n = 7) were open-label trials.
For the present analysis, we only used data from experimental
sessions in which psilocybin was administered alone and at a dose
of at least 115 mg/kg po. Lower psilocybin doses were excluded
because they failed to produce subjective drug effects that were
statistically different from placebo [2,28]. The pooled sample
included 409 psilocybin administrations and 261 subjects. The
administered psilocybin dose ranged from 115 to 315 mg/kg po
(M + SD: 214+63 mg/kg).
Subjects
Participants of all studies were recruited through advertisement
from the local universities and hospital staff and carefully screened
before admission to the studies. Exclusion criteria were as follows:
Personal or family history of schizophrenia, major depression,
bipolar, and borderline personality disorder; personal history of
alcohol or illicit drug abuse; neurological disorders; and abnormal
blood count, electrocardiogram, or blood pressure. Additionally,
most studies excluded subjects with an Emotional Lability score in
the Freiburg Personality Inventory (FPI) [29] more than two
standard deviations above the mean of a normative sample.
Descriptive statistics of the included subjects are presented in
Table 1.
Predictor Variables
Two groups of predictor variables were used: (1) Predictor
variables that only varied between subjects, i.e., were constant
across different drug sessions of the same individual, and (2)
predictor variables that varied between and within subjects.
Predictor variables of the first group were measured at screening
and included age, gender, body mass index (BMI), years of
education, drug use, psychological problems, and stable person-
ality traits, whereas predictor variables of the second group were
either measured at the beginning of each drug session shortly
before drug administration (e.g., measures of the present mood
state) or determined by the design of the experiment (e.g., drug
dose, environment of the drug session, and time of assessment).
Predictors of the first and second group thus describe subject
(Table 1) and session characteristics (Table 2), respectively.
Drug use and pre-experience with classical
hallucinogens. Depending on the study, information on
present and past drug use was obtained by semi-structured
psychiatric interviews or by one of two different versions of
investigator constructed questionnaires. The following categorical
predictor variables were constructed by pooling information from
all available sources: (1) ‘‘Daily smoker’’ is a dichotomous variable
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that is one if the subject smokes at least one cigarette a day and
zero otherwise. (2) ‘‘Alcohol consumption’’ is a dichotomous
variable that is one if the subject drinks more than 60 ml pure
ethanol from alcoholic beverages per month and zero otherwise.
(3) ‘‘THC use’’ is an ordered categorical variable with the three
categories ‘‘never’’ (absolutely no experience with THC), ‘‘rarely’’
(less than once per month), and ‘‘sometimes’’ (at least once per
month). THC use was represented in all regression models as two
dummy coded contrast variables using an ordinal coding scheme.
That is, when both variables were contained in the model, the first
dummy variable represented the difference between ‘‘never’’ and
‘‘rarely’’ and the second between ‘‘rarely’’ and ‘‘sometimes’’. (4)
‘‘Hallucinogen-naı¨ve’’ is a dichotomous variable that is one if the
subject has never used classical hallucinogens, such as psilocybin,
LSD, and mescaline and zero otherwise. Hallucinogen-naı¨ve is the
only drug use variable that could change from one session to
another within the same individual because participations on
earlier experimental psilocybin sessions were also counted as
lifetime hallucinogen experiences. Distributional characteristics of
the four drug use variables are displayed in Table 1.
Zuckerman-Kuhlman Personality Questionnaire (ZKPQ)
[30]. The ZKPQ contains 99 self-referent true/false statements
that cover five major dimensions of personality (1) Impulsive
Sensation Seeking consists of of the two facets Impulsivity (i.e., a
lack of planning and tendency to act quickly on impulse without
thinking) and Sensation Seeking (i.e., a general need for thrills and
excitement and preference for unpredictable situations and
friends). (2) Neuroticism-Anxiety describes emotional upset,
worry, fearfulness, obsessive indecision, lack of self confidence,
and sensitivity to criticism. (3) Aggression-Hostility reflects a
readiness to express verbal aggression; rude, thoughtless or
antisocial behavior; vengefulness; spitefulness; and a quick
temper and impatience with others. (4) Activity consists of the
two facets Need for General Activity (i.e., impatience and
restlessness when there is nothing to do) and Work Activity (i.e.,
a preference for challenging and hard work). (5) Sociability
comprises the two components Parties and Friends (i.e., a liking for
big parties, interacting with many people and having many
friends) and Isolation Intolerance. There is also a control scale, the
Infrequency scale, that serves to eliminate subjects with possibly
invalid records.
Table 1. Descriptive statistics of subjects (n = 261).
Characteristics Valuesa Missings
Age 27.8+6.0 0%
Body mass index 22.2+2.3 25%
Gender 0%
male 62% (161)
female 38% (100)
Education 0%
High school diploma 9% (23)
University students 56% (147)
University graduates 35% (91)
Hallucinogen-naı¨ve 15%
yesb 59% (131)
no 41% (90)
Daily smoker 24%
yes 30% (59)
no 70% (139)
THC use 16%
never 16% (35)
rarelyc 50% (109)
sometimesd 35% (76)
Alcohol consumption 23%
,= 60 ml per month 55% (110)
.60 ml per month 45% (90)
ZKPQ
Impulsive Sensation Seekinge 0.4+0.8 52%
Neuroticism-Anxietye 20.9+0.7 52%
Aggression-Hostilitye 20.6+0.9 52%
Activitye 0.0+0.9 52%
Sociabilitye 20.1+0.9 52%
TAS
Absorptionf 20.8+1.2 72%
SCL-90-R
Global Severity Indexg 20.3+0.9 31%
Note. THC = Tetrahydrocannabinol; ZKPQ = Zuckerman-Kuhlman Personality
Questionnaire; TAS = Tellegen Absorption Scale; SCL-90-R = Symptom Check-
List-90-Revised.
aMeans + standard deviations and frequencies are shown for continuous and
categorical variables, respectively. Numbers in parenthesis indicate absolute
frequencies.
bExperience of a classical hallucinogen at least once in a lifetime previous to the
first experimental day.
cLess than once per month.
d1–10 times per month.
eNormed on the Bielefeld-Jena sample (n= 141) of Angleitner et al. [33].
fNormed on the sample of Ritz et al. [36].
gNormed on a German community sample (n= 1006) [40].
doi:10.1371/journal.pone.0030800.t001
Table 2. Descriptive statistics of psilocybin sessions (n= 409).
Characteristics Valuesa Missings
Psilocybin dose (mg/kg) 214.1+63.0 0%
Psilocybin dose (categorized) 0%
115–125 mg/kg 23% (93)
170 mg/kg 9% (35)
215–225 mg/kg 20% (83)
250–270 mg/kg 38% (157)
315 mg/kg 10% (41)
Time of assessmentb 0%
60–90 min 23% (96)
110–160 min 39% (158)
195–270 min 23% (94)
6–10 h 13% (53)
24 h 2% (8)
Setting 0%
PETc 12% (51)
no PET 88% (358)
aMeans + standard deviations and frequencies are shown for continuous and
categorical variables, respectively. Numbers in parenthesis indicate absolute
frequencies.
bCompletion of OAV or 5D-ASC questionnaire after drug intake.
cDrug sessions involving positron emission tomography (PET) measurements.
doi:10.1371/journal.pone.0030800.t002
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The ZKPQ is the standard instrument for the assessment of
Zuckerman’s alternative Five-Factor Model (FFM) of personality.
In contrast to the classic FFM (the so called ‘‘Big Five’’), which has
been identified by lexical analyses of words describing personality,
the development of the alternative FFM was guided by the
assumption that basic personality traits are those with a strong
biological-evolutionary basis [30]. Consequently, the primary
dimensions of the ZKPQ were identified by factor analyzing
scores on a variety of personality and temperament scales with
known or suspected biological determinants. However, despite
conceptual and methodological differences, joint factor analyses of
the ZKPQ with the NEO-PI-R [31], a well established measure of
the Big Five, suggest a large overlap between the two FFMs [32].
That is, the ZKPQ factors Sociability and Neuroticism-Anxiety
are considered highly convergent with the Big Five factors
Extroversion and Neuroticism, respectively, and the ZKPQ factors
Impulsive Sensation Seeking and Aggression Hostility have shown
at least moderate negative correlations with the Big Five factors
Conscientiousness and Agreeableness, respectively.
The authorized German adaptation of the ZKPQ, which has
shown good psychometric properties in two independent German
samples [33], was used in 11 of the 23 pooled studies and
completed by 125 subjects.
Freiburg Personality Inventory (FPI; half form B)
[29]. The FPI half form B contains 105 self-referent true/false
statements which – according to the authors of the instrument –
measure nine primary and three secondary dimensions of
personality. It was administered as part of the screening
procedure in 16 of the 23 pooled studies and completed by 155
subjects. The FPI measures very similar personality traits as the
ZKPQ. Thus, in order to reduce multicollinearity and to keep the
number of candidate predictors low, we only used the scales of the
FPI for imputing missing values of the ZKPQ, but not for
predicting acute drug responses directly (see statistical analysis
section for additional details). Even though the FPI was more
completely assessed (40.6% missings in the FPI vs. 52.1% missings
in the ZKPQ), we decided to use the ZKPQ and not the FPI for
predicting psilocybin responses because the ZKPQ has undergone
more extensive psychometric testing and is much more widely
used internationally than the FPI half form B.
Tellegen Absorption Scale (TAS) [34]. The TAS is a
widely used self-report questionnaire for assessing the personality
trait Absorption. As measured by the TAS, Absorption refers to an
individual’s openness to a variety of cognitive, perceptual, and
imagistic experiences as well as vivid imagery, synesthesiae, and
intense involvement in aesthetics and nature. The TAS has been
reported to be strongly associated with fantasy proneness, and
modestly with the Big Five factor Openness to Experience and
hypnotic susceptibility [35].
We used the German Version of the TAS [36] with a modified
item response format (i.e., five-point Likert scale ranging from does
not apply (0) to does fully apply (4) instead of the original dichotomous
true or false response), which is the same version as Ott et al. [37]
have used. It was administered in 4 of the 23 pooled studies and
completed by 73 subjects. The internal consistency as well as the
general factor saturation of the TAS in our sample were excellent
(Cronbach’s a= 0.95; McDonald’s vh = 0.75).
Passive-Spontaneous Imagination (PASI). The PASI is a
subscale of the Hallucination Prediction Inventory (HPI-81; Diezi,
Faeh, and Hermann, unpublished master’s thesis, which was
constructed to explain individual differences in experiencing visual
alterations during altered states of consciousness (ASCs). It consists
of 30 four-point Likert scale items measuring the frequencies of
visual phenomena that spontaneously occur during hypnagogic
and hypnopompic states, daydreaming, closed eyes, listening to
music, thinking, and imagining (see Supplementary Table S1, for
an English translation of the PASI items). The PASI was reported
to have good psychometric properties in a normative sample of
442 subjects Diezi, Faeh, and Hermann, unpublished master’s
thesis. Furthermore, in a experiment, in which ASCs were induced
by sensory deprivation (n = 35), the PASI was a strong predictor of
visual hallucinatory phenomena as measured by the Visionary
Restructuralization scale of the Aussergewo¨hnliche Psychische
Zusta¨nde (APZ) [38] questionnaire.
The PASI was administered in 8 of the 23 pooled studies and
completed by 107 subjects. The internal consistency of the PASI in
our sample was excellent (Cronbach’s a= 0.93), and the general
factor saturation was satisfactory (McDonald’s vh = 0.65). There
was also a strong correlation of the PASI with the TAS (r = 0.77,
n = 53), suggesting a large overlap between these two constructs. In
order to reduce redundancy, we only used the PASI to impute
missing values of the TAS, but not for predicting psilocybin
responses directly. Similar to the FPI and ZKPQ, the TAS was
preferred over the PASI even though it had more missing values
(72% missings in the TAS vs. 59% missings in the PASI) because it
is more widely used internationally and has been more extensively
validated.
The Symptom Check-List-90-Revised (SCL-90-R; [39];
German version by [40]). The SCL-90-R is a widely used
self-report inventory designed to screen for a broad range of
psychological problems present in the past four weeks. Each of the
90 items is rated on a five-point Likert scale of distress ranging
from not at all (0) to extremely (4). The items of the SCL-90-R are
assigned to 9 different symptom dimensions: Somatization,
Obsessive-Compulsive, Interpersonal Sensitivity, Depression,
Anxiety, Anger-Hostility, Phobic Anxiety, Paranoid Ideation,
and Psychoticism. However, because these nine dimensions are
not supported by most exploratory and confirmatory factor
analyses and because many studies have pointed to the presence
of a strong general factor [41], only the Global Severity Index
(GSI), which is the total score of all SCL-90-R items, was used as a
predictor variable.
The SCL-90-R was administered as part of the screening
procedures in 14 of the 23 pooled studies and completed by 179
subjects. The internal consistency of the GSI in the pooled sample
was excellent (Cronbach’s a= 0.94), and the general factor
saturation was satisfactory (McDonald’s vh = 0.62).
Adjective Word Lists (‘‘Eigenschaftswo¨rterliste’’; EWL-
60-S and EWL-K). Two different versions of the Adjective
Word List were used to assess the current mental state shortly
before drug administration. The older version EWL-K [42] was
used in studies before the year 2000 (n = 7), whereas the newer
version EWL-60-S [43] was used in later studies (n = 5). Both
questionnaires contain a list of adjectives which must be rated on
how well they describe the current mental state. The EWL-K
contains 123 adjectives and a dichotomous true or false response
format, whereas the EWL-60-S contains 60 adjectives and a
four-point response format ranging from not at all (0) to strongly
(3). In both questionnaires, items are grouped into six main
scales: Performance-Related Activity, General Inactivation,
Extroversion-Introversion, General Well-Being, Emotional Ex-
citability, and Anxiety-Depressiveness. We combined these
scales across questionnaire versions by using only those items
that are contained in both questionnaire versions (see
Supplementary Table S2 for a list of the overlapping items in
each scale). To adjust for the different item response format,
each EWL scale was z-transformed within each questionnaire
version. By combining EWL-K and EWL-60-S, measures of the
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mental state before drug intake were available from 185 of the
409 drug sessions.
Response Variables
Altered States of Consciousness Rating Scales OAV and
5D-ASC. In each experimental session, subjects were asked to
rate drug induced alterations of consciousness by either the OAV
questionnaire [44] or its extended version 5D-ASC [45]. The
OAV was used in studies conducted before the year 2000 (n = 10),
whereas the 5D-ASC was used in all later studies (n = 13). In all
studies, questionnaires were administered during the acute or post-
acute effects of the drug and subjects were asked to rate their
experiences from the moment of drug intake to the time of
assessment. If the questionnaires were completed more than once
during an experimental session, only data from the measuring time
points yielding the highest mean total score were used. The
frequencies of different assessment times in the pooled sample are
shown in Table 2. Because the time of assessment could have
affected subjective drug effects ratings, time (defined as the
logarithm of minutes after drug intake) was included as covariate
in all statistical analyses.
There are 66 visual analogue items that occur in both the OAV
and 5D-ASC and that can be used to assess three primary and one
global dimension of ASCs. The three primary dimensions are
called Oceanic Boundlessness (OBN), Dread of Ego Dissolution
(DED), and Visionary Restructuralization (VRS), and the global
dimension is called Altered States of Consciousness (G-ASC). The
OBN dimension describes highly enjoyable and positively valued
experiences of ASCs, such as deeply felt positive mood,
experiences of unity, transcendence of time and space, spiritual
experiences, and sense of intuitive understanding. Because many
of the OBN items have been directly formulated on the basis of six
of the nine categories of mystical experiences proposed by Stace
[46], high scores on the OBN scale indicate a state similar to
mystical experiences as described in the scientific literature on the
psychology of religion. The DED dimension measures experiences
of cognitive impairment, loss of self-control, feelings of disintegra-
tion or separation from oneself and the world, and anxiety or
panic. High scores on the DED scale therefore indicate a very
unpleasant state similar to so called ‘‘bad trips’’ described by drug
users. The VRS dimension assesses elementary and complex visual
pseudo-hallucinations, audio-visual synesthesiae, increased pro-
duction of vivid imagery from memory or fantasy, as well as
changes in the meaning of percepts. Finally, the secondary scale
G-ASC is the total score of all 66 OAV items and thus can be
considered as a general measure of consciousness alteration.
The OBN, DED, VRS, and G-ASC dimensions have been
hypothesized to be fundamental dimensions of ASCs that are
factorially invariant across ASCs induction methods [38].
However, a recent psychometric investigation of the OAV [25]
has only partially confirmed this hypothesis. Specifically, it has
been found that the VRS factor contains several items that load
more strongly on the OBN factor and that the VRS factor could
be merged with the OBN factor on a high level of construct
hierarchy. Furthermore, all original OAV factors were demon-
strated to be multidimensional. Studerus et al. [25] therefore
constructed and validated eleven new lower order factors that are
more homogeneous than the original factors and that can be used
to describe more specific aspects of ASCs (see [25] for descriptions
of these scales). Nevertheless, because the original factors have
shown relatively strong general factor saturations, they still can be
advantageous for capturing complex criteria. To this end and in
order to compare our results with earlier studies, we decided to use
both the original and the recently constructed subscales as
dependent variables.
Statistical Analysis
To ensure the validity of the assumptions of linear mixed effects
models (i.e., Gaussian distribution of random effects and within-
subjects errors, homoscedasticity, and linearity), an extended
method of Box-Cox transformation [47] was applied to all
response variables. The negative inverse of the square root was
found to be appropriate for the Anxiety factor, and a natural
logarithm transformation worked best for the DED, Spiritual
Experience, Insightfulness, Disembodiment, and Audio-Visual-
Synesthesiae factors. All other response variables were trans-
formed by taking the square root. Predictor variables were not
transformed because partial residual plots indicated that linearity
assumptions were already reasonably well satisfied after trans-
forming the response variables.
As depicted in Supplementary Figure S1, several predictor
variables contained considerable proportions of missing values.
Because the missing data mostly resulted from different study
designs among the pooled studies, the missing data mechanism can
be assumed to be ‘‘missing at random’’ (MAR) or ‘‘missing
completely at random’’ (MCAR) [48]. To minimize potential bias
and loss of information arising form missing data, we used a
statistical technique called multiple imputation (MI) [49]. MI is
regarded as the method of choice for handling complex
incomplete data problems because it yields unbiased parameter
estimates and standard errors under an MAR or MCAR missing
data mechanism and maximizes statistical power by using all
available information [48]. We imputed missing values by the
Multivariate Imputation by Chained Equations (MICE) software
[50], which is freely available as an add-on package to R [51]. The
MICE-package uses fully conditional specification as imputation
method, which means that imputation models can be flexibly
specified on a variable-by-variable basis. We used predictive-
mean-matching, proportional odds models, and logistic regressions
to impute continuous, ordered categorical, and binary variables,
respectively. The scales of the the FPI and PASI questionnaires
were included in the MI procedure as auxiliary variables to
improve the imputation of the ZKPQ and TAS scales,
respectively. For each variable, the set of predictors was restricted
to those that correlated with at least 0.15 with the variable to be
imputed. This resulted in a series of imputation models that
contained the best 9–29 predictors of each target variable. Due to
the relatively large fraction of missing information in some
variables, we generated 20 multiply imputed data sets, which is a
larger number than what the literature historically recommends
[48]. Recent simulation studies (e.g., [52]) show that this has a very
beneficial impact on statistical power, especially when the fraction
of missing information is as high as in the present study.
Convergence of the Gibbs sampling algorithm and the quality of
imputed values were assessed in accordance with recommenda-
tions of Buuren et al. [50].
To ensure that no severe multicollinearity existed between
predictor variables, variance inflation factors (VIFs) were comput-
ed for each predictor variable within in each of the imputed data
sets. Because no VIF was larger than 3, we did not exclude any
predictor variable due to multicollinearity.
Because some subjects participated in more than one psilocybin
study and because some studies involved multiple psilocybin
sessions, our pooled data set contains non-independent observa-
tions. To account for this non-independency, we used linear mixed
models in which the intercepts were allowed to vary per subject.
We also considered more complex mixed effects models with
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varying slopes for the drug dose effects and varying intercepts by
study. However, model comparisons by the Akaike’s information
criterion (AIC) in the full models suggested that the varying
intercept per subject model was sufficient to account for the
clustering in our data.
In order to directly compare regression coefficients of binary
and continuous predictors, continuous predictor variables were
rescaled within each imputed data set by dividing them by two
times their standard deviations. Because binary variables – except
when highly skewed – have a standard deviation of roughly 0.5,
our rescaling procedure resulted in regression coefficients that
reflected the change of the dependent variable for a two standard
deviation change in both binary and continuous predictors (see
also [53]). Outcome variables were z-transformed within each
imputed data set such that regression coefficients were also
comparable across models with different outcomes.
Regression models that contain too many unimportant
predictor variables can result in loss of precision in the estimation
of regression coefficients and the predictions of new responses
[54]. On the other hand, selecting variables by data-dependent
methods (e.g., stepwise approaches) may result in overly optimistic
estimates of predictive ability and model fit and unstable sets of
predictor variables, especially in small data sets [21]. To reduce
these risks, we built our models by combining backward
elimination with a two step bootstrap approach. A major
advantage of this approach is that it also solves the problem of
variable selection under multiple imputation (e.g., [55]).
In the first step, 200 bootstrap samples were taken from each of
the 20 imputed data sets. The bootstrap samples were obtained by
drawing from individual cases (i.e., psilocybin sessions) with
replacement and were of equal sample size as the original sample.
Within each bootstrap sample, parsimonious models were
searched for by applying backward elimination. That is, starting
from the full models, predictors were dropped in a stepwise fashion
until no predictor was left with a Wald test p-value larger than
0.157. This significance level corresponds to selecting predictors
with 1 df based on the AIC [21]. The random intercept for the
subjects was always included in the models and only fixed effects
were considered for elimination. Predictors were ranked according
to their inclusion frequencies in the final models. Those predictors
that were selected in at least 50% of the 20|200 bootstrap
samples were considered important and further analyzed in a
second modeling step. Thus, the first step primarily served to
reduce model space with a minimal risk of eliminating important
predictors (see also [56]).
The second modeling step was very similar to the first step.
Again, 200 bootstrap samples were taken within each imputed
data set and backward elimination was applied with a stopping
rule of p = 0.157. However, this time we began from full models
that included only those predictors that were selected in the first
step. The model that was selected most often across all bootstrap
samples was considered the most stable model and further
explored for relevant interactions. The two step bootstrap
procedure was repeated for each of the 15 response variables.
In each of the resulting 15 final models, the multivariate
associations between the repeatedly measured outcomes and the
fixed effects in the models were estimated by the R2 statistic
proposed by Edwards et al. [57]. To obtain reliable standard
errors, confidence intervals, and associated p-values of the fixed
effects parameters, Markov Chain Monte Carlo (MCMC)
sampling was used. MCMC sampling is a modern alternative to
the conventional significance test of fixed effects in mixed effects
models based on t or F statistics, which is unreliable due to the lack
of a clear definition of the degrees of freedom [58]. For each final
model and each imputed data set, random draws from the
posterior distributions of the parameters were taken and then
mixed across data sets. The mixed draws approximate the
posterior distribution of the pooled parameters and thus can be
used for inference after multiple imputation [59]. A simulation
study by Zhou et al. [60] has shown that this approach leads to
better results than the conventional application of Rubins’s rules
[49], especially when the number of imputed data sets is large.
Results
The selection frequencies of the predictor variables and models
as a result of the bootstrap selection procedures are provided in
Supplementary Table S3. Drug dose was the only predictor
variable that reached a selection frequency of 100% and it did so
with all 15 response variables. The number of predictor variables
that were selected in more than 50% of the bootstrap samples
ranged from 5 for the dependent variable DED to 20 for the
dependent variable Audio-Visual Synesthesiae. BMI and daily
smoker were the only variables that never reached a selection
frequency of 50%. In general, the number of predictor variables
reaching the cutoff of 50% was considerably lower for the original
OAV scales than for OAV subscales (6–7 vs. 16–24). The lower
number of selected variables in the first step also led to more stable
models in the second step. Whereas the most frequently selected
model of the dependent variable OBN was selected in 32.1% of
the cases, the most frequently selected model of the dependent
variable Anxiety was selected only in 0.3% of the cases.
Because drug dose was clearly the most important predictor,
first order interactions between drug dose and all other predictors
were explored within the most frequently selected models. Only 12
of the 15|23 tested interactions were significant at p,0.05 and
only one interaction, namely, PET|Drug Dose predicting
Anxiety, reached significance at p,0.01. The interaction indicated
that Anxiety increased with increasing drug dose in the non-PET
condition, but decreased with increasing drug dose in the PET
condition. However, it should be noted that the variability of the
drug dose variable within the PET condition was very small.
Specifically, only 215 and 250 mg/kg doses of psilocybin were
administered in experiments involving PET measurements. Thus,
the significance of this interaction was considered rather
questionable and not included in the final models.
The variances explained in the full and simplified final models
of all 15 outcome variables are presented in Table 3. As can be
seen from the table, the variable selection procedure only slightly
reduced explained variances, suggesting that the most important
predictors were retained in the models, and the excluded variables
were mostly noise variables. The variance explained in the
simplified models was highest for the OAV total scale (R2 = 0.31)
and lowest for Disembodiment (R2 = 0.163). In general, the main
scales tended to have higher explained variances than the
subscales even though they were explained by a lower number
of predictors.
The size and statistical significance of the regression coefficients
of the most stable models, as estimated by the MCMC sampling
method, are shown in Figure 1. Standard errors and highest
posterior density 95% credibility intervals are additionally
provided in Supplementary Table S3. Overall, drug dose had
the strongest effect on psilocybin response. It was significantly
associated with all outcome variables and had the highest effect
size in all models, except in the models predicting Spiritual
Experience, Anxiety, and Changed Meaning of Percepts. The time
of assessment was positively associated with Spiritual Experience
and Elementary Imagery and negatively associated with DED and
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Impaired Control and Cognition, indicating that disturbances in
control and cognition were less often reported when asked about
later in the session. In experimental sessions involving PET
measurements, participants reported much higher levels of
Anxiety. In fact, of all 24 analyzed predictor variables, PET was
the strongest predictor of Anxiety, and its effect size was more than
twice as high as the one of drug dose. Compared to younger
subjects, older subjects reported less Impaired Control and
Cognition and also showed a trend for more Blissful State
(p = 0.059). Years of education, gender, and BMI were not
significantly associated with any response variable.
Drug use and pre-experiences with hallucinogenic drugs only
moderately affected psilocybin responses. Although hallucinogen-
nave subjects tended to report stronger effects in most outcome
variables, statistical significance was only reached for Disembodi-
ment, VRS, and Changed Meaning of Percepts. Psilocybin
responses did not differ between subjects who never consumed
THC and those who rarely consumed THC. However, subjects
who sometimes smoked cannabis (more than once per month)
reported significantly more Blissful State than subjects who rarely
consumed cannabis (less than once per month) and also showed a
trend for less Anxiety (p = 0.07). There were also statistically
significant positive associations between alcohol consumption and
experience of Audio-Visual Synesthesiae and Complex Imagery.
The mental state immediately before drug intake had a
relatively strong influence on several outcome variables.
Specifically, Performance-Related Activity, which was measured
by the adjectives go-getting, avid, active, and energetic, had a
major influence on the overall consciousness alteration (G-ASC)
and on several experiences covered by the OBN and VRS
dimensions. Emotional Excitability was strongly positively
associated with Spiritual Experience and Anxiety and moder-
ately with all OAV main scales, as well as Insightfulness and
Audio-Visual Synesthesiae. Anxiety-Depressiveness before drug
intake did not lead to significantly more unpleasant experiences
during the sessions.
The GSI scale of the SCL-90-R was negatively associated with
OBN, Blissful State, and Complex Imagery, indicating that
subjects who experienced more psychological problems previous
to the experiments reported less pronounced effects with these
scales. Except for Absorption, which strongly predicted several
experiences measured by the OBN and VRS dimensions, most
personality traits did not have a major influence on psilocybin
responses. Of the personality traits constituting Zuckerman’s
alternative five-factor model, only Sociability was significantly
associated with any outcome variable. Specifically, subjects who
were more sociable (i.e., outgoing and extroverted) reported less
Spiritual Experience and more Audio-Visual Synesthesiae.
The fractions of missing information (FMI) and the relative
increases in variance due to missingness (RIV), which quantify the
missing data’s influence on the sampling variance of the parameter
estimates, are shown in Supplementary Table S3. For all imputed
variables, FMI values were lower than their missing data rates,
which indicates that the variables in the imputation model were
predictive of the missing values. Because some of the information
loss was mitigated by borrowing information from correlated
variables, increases in sampling errors of the regression coefficients
were not completely commensurate with overall reductions in
sample sizes. Not surprisingly, the RIV was largest for Absorption
(0.94 on average), which was also the variable with the highest
missing data rate. This indicates that the confidence interval of the
regression coefficient for Absorption was on average about 0.94
times larger than it would have been if this scale had no missing
values.
Discussion
The present study sought to predict acute responses to
psilocybin when administered in a controlled scientific setting to
healthy volunteers. The relative importance of 24 predictor
variables from a wide range of domains were investigated.
Drug dose was clearly the most important predictor of
psilocybin response. It was the only predictor that was always
retained in automatic variable selection and its effect size was
largest in 12 of the 15 final prediction models. Furthermore, its
effect on general consciousness alteration, as measured by the
OAV total scale, was more than twice as high as that of other
predictors. The personality trait of Absorption was found to be the
second most important predictor of psilocybin response. It was
highly positively associated with the overall consciousness
alteration and strongly predicted mystical-type experiences and
visual effects induced by psilocybin. Further variables that were
found to be important for predicting psilocybin response were
Performance-Related Activity, Emotional Excitability, psycholog-
ical distress as measured by the GSI, pre-experience with classical
hallucinogens, frequencies of THC and alcohol consumption,
Sociability, time of assessment, and setting (PET vs. no PET
measurement). Being in an emotionally excitable and active state
immediately before drug intake, having experienced few psycho-
logical problems in the past weeks, no previous experience with
classical hallucinogens, and moderate THC and alcohol con-
sumption increased the intensity of pleasurable effects and/or
visual alterations, whereas settings involving PET measurements,
Emotional Excitability, and low age contributed to the experience
of unpleasant and/or anxious reactions.
The finding that Absorption was amongst the most important
predictors of psilocybin-induced ASCs is consistent with a large
number of studies showing that Absorption is associated with
Table 3. Variance explained (Edward’s R2) in the full and
simplified models.
Outcome Full Simplified
models models
Main scales
Altered state of consciousness 0:337 0:310
Oceanic boundlessness 0:293 0:266
Dread of ego dissolution 0:232 0:182
Visionary restructuralization 0:333 0:293
Subscales
Experience of unity 0:221 0:196
Spiritual experience 0:249 0:220
Blissful state 0:195 0:179
Insightfulness 0:225 0:184
Disembodiment 0:175 0:163
Impaired control and cognition 0:202 0:192
Anxiety 0:201 0:187
Complex imagery 0:237 0:229
Elementary imagery 0:205 0:194
Audio visual synesthesiae 0:226 0:217
Changed meaning of percepts 0:234 0:221
doi:10.1371/journal.pone.0030800.t003
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differential responsivity to various ASC induction procedures,
including hypnosis, meditation, marijuana intoxication, and
electromyograph biofeedback [61,62]. Absorption has also been
reported to be positively associated with the occurrence of
synesthesiae after the ingestion of ayahuasca [16], a hallucinogen
with similar modes of action as psilocybin. This is in agreement
with our results, which showed that, of all 15 response variables,
Absorption most strongly predicted Audio-Visual Synesthesiae. A
recent study by Ott et al. [37] suggests that inter-individual
differences in Absorption and responsiveness to hallucinogenic
drugs could be both related to the binding potential of the 5-HT2A
receptor, which is the main site of action of serotonergic
hallucinogens, such as psilocybin [8]. Although Ott et al. [37]
have demonstrated a significant association between T102C
polymorphism affecting the binding potential of the 5-HT2A
receptor and the TAS scale, they did not assess the association
between TAS and responsivity to serotonergic hallucinogens. The
present study is filling this gap, as it is, to our knowledge, the first
study predicting the effects of a classical hallucinogen by
Absorption in a large sample of subjects.
Apart from a strong influence of Absorption and a relatively
minor influence of the ZKPQ factor Sociability, which is highly
convergent with the Big-Five factor Extroversion [32], personality
traits only marginally contributed to the prediction of psilocybin
responses. This is rather surprising because personality traits have
been postulated by many authors to be among the most important
determinants of hallucinogen response (e.g., [11,12]). It is also
worth noting that we did not detect any statistically significant
relationship between Neuroticism-Anxiety and negative reactions
to psilocybin. This finding contradicts several earlier, smaller
scaled studies [13–15], which have found moderate to strong
correlations between Neuroticism and anxious reactions to
classical hallucinogens and which have led to our policy of
excluding subjects with very high Neuroticism scores (i.e., more
than two SD above the mean) at screening. Although the exclusion
of highly neurotic subjects could have distorted our sample and
thus reduced the predictive ability of Neuroticism, it should be
noted that the chosen cutoff affects only the highest 2.3% of the
normal distribution and that there was still substantial variability
of Neuroticism in our sample. Nevertheless, as has been shown in
Table 1, both mean and variance of Neuroticism in our sample
where somewhat reduced compared to normative data. Hence, we
cannot rule out the possibility that Neuroticism increases the risk
of adverse reactions in the highest tail of the distribution. A
positive relationship between Neuroticism and the effects of
classical hallucinogens would also be biologically plausible because
a recent PET study has demonstrated a positive correlation
between Neuroticism and frontolimbic 5-HT2A receptor binding
Figure 1. Regression coefficients of the final models pooled across 20 imputed data sets. The effects are adjusted for the influences of all
other variables in the models. One, two, and three asterisks represent p-values v0.05, 0.01, and 0.001, respectively.
doi:10.1371/journal.pone.0030800.g001
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[63]. Thus, excluding highly neurotic subjects at screening might
still be a sensible approach for increasing the safety of controlled
experiments involving hallucinogen administration.
In contrast to personality factors, current mood state and
psychological distress in the past four weeks before drug intake
were generally more important for predicting psilocybin response
in this study. This is in agreement with the existing literature. For
instance, Metzner et al. [17] have found that the best predictor for
mood during the psilocybin session was mood before the session,
and Dittrich [14] reported that Emotional Lability, a factor that
was predominantly measured by state variables, most strongly
increased the likelihood of experiencing DED after DMT
administration. Interestingly, we have found that Emotional
Excitability shortly before drug intake predicted anxious reactions
to psilocybin much better than Anxiety-Depressiveness. However,
this could also be due to statistical reasons. Whereas Emotional
Excitability was measured by 11 items, Anxiety-Depressiveness
was measured by only 4 items that additionally also had relatively
high item difficulties. Consequently, the variability – and possibly
also the reliability – of Anxiety-Depressiveness was substantially
lower than that of Emotional Excitability. It should also be noted
that these two factors were relatively highly correlated in our
sample (r = 0.5), which frequently might have led to the inclusion
of only one of these two variables in automatic model selection.
The finding that Performance-Related Activity was amongst the
most important predictors of experiences described by the OBN
and VRS dimensions has, to our knowledge, not been described in
the literature before. One possible explanation is that the items
assessing Performance-Related Activity (i.e., go-getting, avid,
active, and energetic) not only captured variance associated with
fitness and energy, but also variance with positive mood and
general optimism. Correlations with EWL subscales (not reported)
are in support of this hypothesis because they reveal that
Performance-Related Activity is most strongly associated with
the EWL subscale Heightened Mood (r = 0.47).
The finding that the PET environment was strongly associated
with anxious reactions could be partially explained by the
perceived atmosphere at the PET center. Whereas non-PET
experiments were mostly conducted in laboratory rooms that were
furnished in an aesthetically pleasing way, the environment at the
PET center was much more clinical and ‘‘antiseptic’’ (i.e., lots of
technical equipment, white walls, personnel in white lab coats).
Our results are therefore in support of current safety guidelines
[26], which recommend avoiding ‘‘cold’’ and overly clinical
environments in human hallucinogen research in order to reduce
the risk of anxious reactions. Although we have found increased
Anxiety in PET experiments, that does not mean that psilocybin
experiments involving PET measurements are unsafe. The
percentage of strong anxious reactions in the PET experiments
was still relatively low, and all of them could be successfully
managed by providing interpersonal support. Furthermore, there
are other factors that might have contributed to the increased
Anxiety in the PET environment. For instance, in contrast to non-
PET experiments, subjects could have their eyes closed while lying
in the scanner and they were less distracted by performing tasks.
Thus, they could concentrate more on the experience, which in
turn might have increased the confrontation with inner fears.
Our results indicate that, in contrast to MDMA [64], the
effects of psilocybin were not moderated by gender. This is
consistent not only with earlier studies investigating the subjective
effects of classical hallucinogens in humans [3,19], but also with
neuroimaging studies, which have found no gender differences in
5-HT2A receptor binding in cortical regions [63,65]. The only
demographic variable that was statistically significantly associated
with any psilocybin response in this study was age. Specifically,
older subjects reported less Impaired Control and Cognition and
tended to experience more Blissful State compared to younger
subjects. These associations are similar to those observed by Hyde
[19] and Metzner et al. [17] and could be explained by an
increased experience with managing occurrent negative emotions
in older people [66]. It is also consistent with the fact that 5-HT2A
receptors densities decrease with increasing age (e.g., [65]).
The finding that hallucinogen-naı¨ve subjects reported slightly
more VRS, Disembodiment, and Changed Meaning of Percepts is
consistent with the study of Metzner et al. [17], which found that
previous experience with classical hallucinogens was negatively
associated with the number of somatic symptoms and visual
alterations induced by psilocybin. However, our results disagree
with those of Dittrich [14], who found that familiarity with drug-
induced ASCs was not predictive of any acute effects of DMT, as
measured by the OAV questionnaire. One possible explanation of
this discrepancy might be that the predictor variable ‘‘familiarity
with drug-induced ASCs’’ in the study of Dittrich not only
included pre-experience with classical hallucinogens, but also
other psychotropic substances.
Although subjects were asked to rate their experiences in
retrospect and mostly during or after the peak effects of the drug,
Impaired Control and Cognition induced by psilocybin was rated
as less intense and Spiritual Experience and Elementary Imagery
were rated as more intense when questionnaires were completed
later in the sessions compared to earlier in the sessions. These
findings are in agreement with a study of Linton et al. [67], which
found that subjects tended to forget ego-alien and threatening
aspects of an LSD experience more often than those dealing with
affects or changes in the perceived meaning of events. Although it
is tempting to explain these associations by the well-known
phenomenon of ‘‘motivated forgetting’’ [68], they could also have
resulted from differential time courses of psilocybin effects (e.g.,
see [2]).
Limitations
The present study has several limitations. First of all, the design
of our study does not allow causal interpretations of predictor
effects. Although we analyzed data from experimental studies, the
only variable that was systematically manipulated was drug dose
and only within, not between, studies. Hence, with the exception
of drug dose, associations between predictors and outcomes are
purely observational.
Although several statistically significant relationships between
non-pharmacological predictors and outcome variables were
detected, there were still relatively large proportions of unex-
plained variances in the outcome variables. For instance, more
than 80% of the variance of the outcome variable Anxiety was left
unexplained, suggesting that there is considerable unpredictability
in anxious reactions to psilocybin – even under highly standard-
ized conditions.
Generalizations of our results are hindered by the composition
of our sample and the circumstances in which psilocybin was
administered. For instance, our subjects were relatively young,
highly educated, and high-functioning. They had more pre-
experiences with classical hallucinogens and cannabis than their
corresponding age group in the general population and also
showed low Neuroticism-Anxiety scores (i.e., almost one SD below
the mean of a normative sample). The distortions in our sample
most likely resulted from our recruitment method, which is prone
to self-selection bias (see also [2]). The specific composition of our
sample and the fact that psilocybin was administered in a carefully
monitored research environment might have reduced the
Prediction of Psilocybin Response
PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e30800
occurrence of unpleasant reactions (i.e., so called bad or horror
trips). This in turn might have lowered our ability to detect risk
factors for unpleasant reactions.
The individual studies that were pooled for the present analysis
were not specifically designed to investigate predictors of
psilocybin response. Consequently, the predictor variables ana-
lyzed herein are not necessarily those that – according to the
literature – would be most promising to investigate. Although the
studied predictors cover the most important domains, some of
them are clearly underrepresented. For instance, the influence of
the setting was only covered by the PET vs. no PET variable.
Furthermore, expectancies of the subjects, which are well known
to influence the effects of most psychoactive drugs, including
alcohol and nicotine [69], could not be studied because no such
variables were obtained.
Because the majority of the pooled studies used double-blind
placebo-controlled designs, one might argue that we could have
controlled for expectancy effects by including the response to
placebo as a covariate into the analyses. Unfortunately, the effects
of psilocybin were so strong that most subjects could easily
differentiate them from placebo. Moreover, because the items of
the OAV questionnaire are visual analogue, anchored no, not more
than usual on the left and yes, much more than usual on the right, most
subjects placed marks at the left end of the scale for all items once
they were convinced that they had received placebo. Consequent-
ly, mean and variances of the OAV scales were essentially zero
under placebo, which severely limited the usefulness of these scales
as covariates. While some investigators have used an active
placebo to increase the success of the double blind in experiments
involving hallucinogens (e.g., [70]), an even better approach for
separating pharmacological effects from the cognitive expectations
of receiving the drug and its effect might be the so called balanced-
placebo design (BPD) [71]. The BPD is a 2|2 factorial design that
crosses the administered substance (drug vs. placebo) with an
instructional set manipulation (subjects are told they receive the
active drug vs. subjects are told they receive placebo). To our
knowledge, the BPD has not yet been used in experiments with
classical hallucinogens, but a recent study has demonstrated its
feasibility with marijuana [72]. It is therefore conceivable, that the
BPD could also foster our understanding of expectancy effects in
responses to classical hallucinogens.
Another limitation of the present investigation is that responses
to psilocybin, as measured by the OAV, could be confounded by
individual differences in the interpretation of the item anchors at
the right end of the visual analogue scale. Specifically, the anchor
yes, much more than usual could have had different meanings
depending on whether the subject has experienced profound ASCs
before. Future studies should therefore validate our results by also
using behavioral measures and/or external raters for assessing
psilocybin response.
In the present study, we have only predicted single aspects of
ASCs. Another approach, taken by Barr et al. [12], is to predict
patterns of psilocybin responses. This could be accomplished by
cluster analyzing individual responses using Pearson correlations
as a proximity measure. The response clusters could than be
predicted by multinomial regression models. Because psilocybin,
especially with higher doses, sometimes can elicit responses that
are not only quantitatively but also qualitatively different [1], it is
possible that a categorical approach would be better suited to
detect determinants of profound ASCs, such as mystical-type
experiences or so called ‘‘horror trips’’. The main reason why we
did not follow such an approach in this investigation is that these
experiences only occurred in a small proportion of our subjects (cf.
[2]). Hence, even with our large sample, the event-per-variable
ratio and statistical power were considered too low for such an
analysis.
A few further statistical issues are worth noting. Although we
used a two-step bootstrap procedure to protect against the dangers
of data-driven model selection, the stability of some prediction
models were relatively low. For instance, the most frequently
selected model of the outcome variable Anxiety was selected in
only 0.3% of the cases, and there were many competing models
that were only slightly less frequently selected. Thus, there was
considerable uncertainty in some of the final models, which could
have introduced bias in the estimation of regression coefficients
and confidence intervals [21]. The natural remedy for this
problem would have been to base inference on a set of competing
models using model averaging and the selection frequencies as
model weights [56]. However, because our analysis was already
complicated by the fact that we had used mixed effects models in
combination with multiple imputation, we did not want to
introduce additional complexity into the analysis and therefore
abstained from performing frequentist model averaging.
The relatively large proportion of imputed values in some
predictor variables (up to 70%) might cause distrust in our
results. However, it should be noted that the applied MI
procedure completely protects against false inference, as long as
the missing data mechanism is correctly modeled and the MAR
or MCAR assumptions are met [48]. Even a predictor with 90%
missing values could still be estimated with MI, albeit with
relatively large uncertainty [21]. There are several reasons why
we believe that the high missing data rate is not a major problem
in the present investigation. First, the MAR assumption is highly
plausible because missing data almost exclusively resulted from
different study designs among the pooled studies. Second, the
number of imputed data sets was relatively high, which is
recommended with large proportions of missingness [48]. Third,
even for the predictor with the highest missing data rate (i.e.,
Absorption), the loss of statistical power induced by missingness
was moderate and did not inhibit the detection of statistically
significant associations.
Conclusions
Although drug dose was clearly the most important determinant
of psilocybin response, the results of this study confirm that a
substantial proportion of the intra- and interindividual differences
in acute responses to psilocybin is related to differences in set and
setting. The results suggest that important predictors of psilocybin
response can be found in a wide range of different domains,
including personality, current mood, psychopathology, drug pre-
experience, demography, and environment.
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